FDA & CMS in talks on pharmacogenomics coverage
This article was originally published in Clinica
Executive Summary
The US FDA is in the early stages of collaborating with the Centers for Medicare & Medicaid Services (CMS) on measures that might boost access to pharmacogenomics tests. "Reimbursement for pharmacogenomic tests has been a particular impediment to wider adoption of those tests," noted FDA deputy commissioner Scott Gottlieb.